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A B S T R A C T
Background: Denmark has a high incidence rate of candidaemia. A Nordic study suggested a higher Danish
prevalence of haematological malignancies as an underlying reason. This nationwide study ascertained
clinical characteristics of Danish candidaemia patients and investigated potential factors contributing to
the high incidence and mortality.
Methods: Microbiological and clinical data for candidaemia patients in 2010-2011 were retrieved.
30-day mortality was estimated by hazard ratios (HR) with 95% conﬁdence intervals (CI, Cox
regression).
Results: Data were available for 912/973 candidaemia episodes (93.7%). Intensive care unit (ICU) held the
largest share of patients (43.2%). Prevalent host factors were multi-morbidity (2 underlying diseases,
74.2%) and gastrointestinal disease (52.5%). Haematological disease was infrequent (7.8%). Risk factors
included antibiotic exposure (90.5%), CVC (71.9%) and Candida colonisation (66.7%). 30-day mortality
was 43.4%, and 53.6% in ICU. Mortality was lower for patients with recent abdominal surgery (HR 0.70,
95% CI: 0.54-0.92).
Conclusion: A substantial prevalence of multi-morbidity and a high 30-day mortality was found. We
hypothesise, that an increasing population of severely ill patients with prolonged supportive treatment
and microbiological testing may in part explain the high candidaemia incidence in Denmark. Nationwide
studies are warranted to clarify this issue.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Candida species account for the majority of fungal bloodstream
infections (BSIs) and the 30-day mortality ranges from 22-70%
(Puig-Asensio et al., 2016; Lortholary et al., 2014; Chakrabarti et al.,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
K.R. Lausch et al. / International Journal of Infectious Diseases 76 (2018) 58–63 592015; Nucci et al., 2013; Chen et al., 2006; Cleveland et al., 2012;
Luzzati et al., 2016).
Denmark is known for a consistently high annual incidence rate
of candidaemia of 7.6-11.0 episodes per 100,000 inhabitants since
nationwide surveillance was introduced in 2004. In comparison,
annual rates of 3.9-4.4 episodes per 100,000 inhabitants have been
reported in similar studies from neighbouring Scandinavian
countries (Arendrup et al., 2013; Hesstvedt et al., 2017; Arendrup
et al., 2008). Nationwide annual data from other countries are
sparse and limited to Australia with 2.4 per 100,000 inhabitants
(Chapman et al., 2017), and Scotland with 4.1 per 100,000
inhabitants (Rajendran et al., 2016). Multiple regional popula-
tion-based studies have been conducted, most of which have also
reported lower incidence rates than in Denmark, with exception of
Atlanta (13.3/100,000) and Baltimore (26.2/100,000) in 2008-11
(Cleveland et al., 2012). A recent comparison of candidaemia
incidence across the Nordic countries suggested that a higher
prevalence of haematological malignancies and higher utilisation
of certain anti-bacterial drugs in Denmark could potentially
explain the higher candidaemia rate (Hesstvedt et al., 2017).
However, clinical characteristics of candidaemia patients, includ-
ing underlying diseases and common risk factors, have not
previously been included in nationwide studies.
The aim of this nationwide cohort study was to ascertain
clinical characteristics of Danish candidaemia patients to identify
high-risk patient groups in order to identify potential factors
contributing to the high incidence in Denmark, and to assess
prognostic factors associated with 30-day mortality in candidae-
mia patients.
Materials and methods
Setting, study population and data collection
The Danish health care system provides tax-supported health
care for all citizens. There is free access to primary care provided by
general practitioners, secondary care in non-university hospitals,
and tertiary care in university hospitals. Departments of medicine
provide both specialised and general care and are operated by
multiple sub-specialities. Each resident in Denmark is assigned a
unique personal identiﬁcation number at birth or immigration,
whichallows individual-level linkage betweenhealth careregistries.
This study included all unique episodes of Candida BSI in
Denmark 1st January, 2010 to 31st December, 2011. Cases were
identiﬁed as part of the ongoing national fungaemia surveillance
programme, where the national Reference Mycology laboratory
ensured completeness of cases through comparison with local
laboratory reports (Arendrup et al., 2013, 2011a). Local clinical
microbiologists collected patient data using an abstraction form
including information on underlying diseases, department at time
of candidaemia diagnosis, surgical procedures, central venous
catheter (CVC), total parenteral nutrition (TPN), and antibacterial
treatment. Paediatric cases (age <16 years of age) were included in
the initial analyses of cases and departments, but later excluded,
due to their separate risk factors and mortality rates.
Deﬁnitions
We included ﬁrst episodes of candidaemia and recurrent
episodes as deﬁned in the Supplementary Table 1, where also
deﬁnitions of baseline characteristics, treatment before blood
culture collection (BCC), and underlying diseases are provided.
Candidaemia was deﬁned as a blood culture positive for Candida
and a recurrent episode if more than 30 days between isolates
(Nucci et al., 2013; Cleveland et al., 2012; Puig-Asensio et al., 2014;
Barchiesi et al., 2015). Multi-morbidity was deﬁned as the presenceof two or more underlying and pre-existing diseases (Whitson and
Boyd, 2017). The Candida Score was used to assess multiple risk
factors (3 points) assigning one point each for TPN, abdominal
surgery, colonisation, and two points for sepsis (León et al., 2006;
Leroy et al., 2011).
Data on Candida species identiﬁcation and susceptibility were
extracted from the national reference laboratory at Statens Serum
Institut. Procedures and isolates within the study period have been
described elsewhere (Arendrup et al., 2013).
Data on hospital admissions and mortality
Rate of incidence per 100,000 population-year were calculated
using population data and rates according to hospital admission
were expressed as numbers of cases per 1000 admissions, using
data obtained from Statistics Denmark (www.statistikbanken.dk).
Data on Intensive Care Unit (ICU) admissions were obtained from
the Danish Intensive Care Database Annual report from 2011
(Fynbo Christiansen, 2011). Mortality data were obtained from the
Danish Civil Registration System, in which the vital status of all
Danish citizens, including deaths and emigrations, are registered
and updated daily (Pedersen, 2011). Early mortality was deﬁned as
death before blood culture results became available to the treating
physician.
Ethics approval
Data collection was approved by the Danish Health authorities
(Journal no 3-3013-364/1/) and the Danish Data Protection Agency
(Journal no 2004-54-1627).
Statistical analyses
Quantitative variables were reported as median with inter-
quartile range (IQR) and qualitative variables were reported as
numbers (%). Categorical data were analysed using the chi-squared
or Fisher exact test. Signiﬁcance was set at a p-value of <0.05. For
survival analysis follow-up was initiated on the collection date for
the positive blood culture. Prognostic factors associated with 30-
day mortality were assessed using Cox regression modelling to
estimate hazard ratios (HR) with 95% conﬁdence intervals (CI) for
the main risk factors and commonly associated underlying
diseases. Only the ﬁrst episode of candidaemia was included in
survival analysis to preserve the assumption of independence of
observations. Directed acyclic graphs (DAG) were used to evaluate
confounders potentially inﬂuencing the relationship between
mortality and candidaemia according to the published literature
for the multivariate analyses (Supplementary Figure 2-10) (Textor
et al., 2017). All statistical analyses were performed with Stata1, vs
14 (StataCorp).
Results
A total of 973 episodes of candidaemia were identiﬁed during
the 2-year study period. Clinical data were available for 912 (93.7%)
episodes, hereof 882 adults (Supplementary Figure 1). The national
annual incidence rate of ﬁrst episodes of candidaemia was 8.8
episodes per 100,000 population-years, 0.38 episodes per 1,000
admissions; the rate was 6.08 episodes per 1,000 ICU admissions,
speciﬁcally.
Most candidaemia episodes were diagnosed in the ICU (43.2%)
(Table 1). General departments of medicine and surgery accounted
for 19.3% and 16.8%, respectively, whereas other departments each
accounted for <5% of the cases including gastroenterology (4.4%),
haematology (3.9%) and oncology (1.2%). Paediatric patients
accounted for 3.3% of cases.
Table 1
Type of department at the time of candidaemia diagnosis and basic demographic data.
Patients Age (years) Male gender
No % Median IQRa % >75 y %
Total 912 100.0 66 56-75 28.3 59.9
Intensive care unit 394 43.2 67 58-75 25.9 61.7
Departments of medicine 306 33.6 65 54-76 28.4 59.9
General Medicine 176 19.3 70 58-80 40.9 58.5
Gastroenterology 40 4.4 54 47-62 5.0 65.0
Haematology 36 3.9 59 48.5-68 11.1 67.4
Cardiology 18 2.0 64.5 59-71 16.7 83.3
Nephrology 14 1.5 58.5 57-76 28.6 50.0
Oncology 12 1.2 66 61.5-70.5 8.3 25.0
Infectious Diseases 9 1.0 45 34-69 11.1 55.6
Neurology 1 0.1 17 - - 100.0
Departments of Surgery 166 18.2 70 61-78 35.5% 54.8
General Surgery 153 16.8 70 62-78 35.3 54.9
Urology 13 1.4 63 56-75 38.5 53.9
Paediatrics 30 3.3 1 0-4 0 60.0
Emergency department 16 1.8 81.5 60-87.5 62.5 56.3
a IQR: Interquartile range.
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years (IQR 57-75 years) for adult candidaemia, but varied
according to department and was highest for departments of
emergency (81.5 years, IQR: 60-87.5), followed by departments of
general medicine and surgery (median 70 years, IQR: 60-79)
(Table 1). Males accounted for 59.9%.
Host and risk factors among adult patients
Prevalent host factors, found in more than half of the patients,
were multi-morbidity (74.2%), including a third with 3 underly-
ing conditions, and gastrointestinal disease (52.5%), including 106
patients (12.0%) with short bowel disease or pancreatic disease
(Table 2). In contrast few patients had an underlying haemato-
logical disease (7.8%). Prevalent risk factors were prior antibiotic
exposure (90.5%), CVC (71.9%), and colonisation with Candida
(66.7%) The proportion of patients with a Candida score of 3 was
highest in the ICU setting (22.6% vs. 15.4% overall). The proportion
of patients receiving TPN was equal in all settings (overall 23.8%).
Neutropenia was infrequent (3.3% of all patients) and associated
with haematological disease in 79.3% (23/29) of the cases. Only 11
(1.2%) patients had no recorded underlying diseases, other than an
“acute infection” diagnosed prior to their candidaemia.
Mortality
Mortality analyses included the 852 primary cases (Supple-
mentary Figure 1). Across all departments, a substantial proportion
of patients (6% in surgery, 13.3% in medicine, and 17.7% in ICU) died
before the results of blood cultures were available (Table 2).
Compared with patients surviving longer, these patients were
characterized by higher age (median age 72 years (IQR: 60- 79)
versus 66.5 (IQR 57- 75)), more prevalent ICU stays (56.9% vs 42.6%,
p-value 0.003), and fewer had a CVC (62.6% vs 73.5%, p-value 0.013)
or received TPN (16.3% vs 25.1%, p-value 0.033).
The overall 30-day mortality was 43.4%, ranging from 53.6%
among ICU patients to 34.8% among non-ICU patients. Mortality
was lowest for departments of general surgery (30-day mortality of
24.8%) (Table 2). The 30-day mortality rate was, in multivariate
analysis, numerically lower for patients with gastrointestinal
disease (adjusted HR 0.85 95% CI: 0.69 -1.04) or solid tumours
(adjusted HR 0.81, 95% CI: 0.62 - 1.06), and signiﬁcantly lower forpatients with abdominal surgery (adjusted HR 0.70, 95% CI: 0.54 -
0.92) when compared with patients without these conditions
(Table 3). Conversely, haematological disease was associated with
a numerically higher mortality (age adjusted HR 1.35, 95% CI: 0.95 -
1.91). High level of multi-morbidity (3 underlying diseases) was
associated with higher mortality compared to non-multi-morbidi-
ty (1 underlying diseases) (adjusted HR 1.21 95% CI: 0.92 - 1.59),
whereas a Candida score 3 was not associated with increased
mortality compared with patients with low score (adjusted HR
1.06, 95% CI: 0.80 - 1.41) (Table 3). There were no differences in
mortality by infecting Candida species (data not shown).
Discussion
In this nationwide cohort study, the incidence of candidaemia
was highest in the ICU, accounting for more than 40% of all cases.
Essentially all patients had underlying diseases and the majority
multi-morbidity. Most common conditions were gastrointestinal
disease, lung disease, and solid tumours. Risk factors were
common and most frequent among patients in the ICU: prior
antibiotics, CVC, colonisation with Candida, BCC from internal line,
prior infection, and abdominal surgery. The overall 30-day
mortality was 43%, highest in ICU patients (53.6%). Mortality
was signiﬁcantly lower among patients with recent abdominal
surgery and numerically lower in patients with gastrointestinal
disease and solid tumours, compared with patients without these
conditions.
The overall incidence rate per admission was similar to rates
reported from other candidaemia studies (0.21-0.89) although
population based incidence rates were high (Chen et al., 2006;
Puig-Asensio et al., 2014; Trouvé et al., 2017). One plausible
explanation for this discrepancy is different registration practises
for numbers of admissions in different countries. In Denmark,
patient referrals between departments are registered as separate
admissions, which inﬂates the denominator. A higher number of
overall admissions in Denmark might also be explained by
Denmark’s easily accessible public health care system. On the
other hand, our ﬁnding of an incidence of 6.08 episodes/1.000
admissions in the ICU is markedly higher than ICU rates reported in
studies from ICU settings in Italy (3.4 episodes/1000 admissions)
(Barchiesi et al., 2015) and France (3.5 episodes/1,000 admissions)
(Baldesi et al., 2017). Part of this may be explained by the
Table 2
Patient characteristics by specialty.
Total (n = 882) ICU (n = 394) General Medicine (n = 176) General Surgery (n = 153)
No. (%) No. (%) No. (%) No. (%)
Baseline characteristics
Prior infection 320 (36.3) 132 (33.5) 85 (48.3) 33 (21.6)
Sepsis 100 (11.3) 52 (13.2) 17 (9.7) 10 (6.5)
Neutropenia 29 (3.3) 5 (1.3) 1 (0.6) 0 (0)
LOS before BCC, median days (IQR)a 12 (5, 23) 10 (6, 19) 11 (5, 30) 17.5 (7, 32)
BCC from internal lineb 245 (36.3) 166 (53.6) 19 (14.8) 17 (13.4)
Colonised with Candida before BCC 588 (66.7) 311 (78.9) 100 (56.8) 77 (50.3)
Candida score 3c 136 (15.4) 89 (22.6) 43 (7.4) 15 (9.8)
Treatment before BCC
Antibiotics 775 (90.5) 373 (95.9) 140 (82.8) 122 (84.1)
Central venous catheter (CVC) 634 (71.9) 351 (89.1) 74 (42.1) 102 (66.7)
Abdominal surgery 234 (26.5) 133 (33.8) 14 (8.0) 69 (45.1)
Total parenteral nutrition (TPN) 210 (23.8) 100 (25.4) 39 (22.1) 39 (25.5)
Corticosteroids 167 (18.9) 92 (23.4) 26 (14.8) 14 (9.2)
Dialysis 141 (16.0) 99 (25.1) 9 (5.1) 6 (3.9)
Chemotherapy 77 (8.7) 20 (5.1) 6 (3.4) 8 (5.2)
Underlying diseases
Gastrointestinal disease 463 (52.5) 203 (51.5) 72 (40.9) 109 (71.3)
Lung disease 231 (26.2) 136 (34.5) 48 (27.3) 24 (15.7)
Solid cancer 170 (19.3) 61 (15.5) 21 (11.9) 61 (39.9)
Chronical heart disease 168 (19.1) 100 (25.4) 31 (17.6) 18 (11.8)
Renal disease 142 (16.1) 44 (11.2) 32 (18.2) 20 (13.1)
Endocrine disease 133 (15.1) 59 (15.0) 39 (22.2) 15 (9.8)
Alcohol and/or iv abuse 111 (12.6) 52 (13.2) 29 (16.5) 9 (5.9)
Haematological disease 69 (7.8) 22 (5.6) 8 (4.6) 3 (2.0)
Multi-morbidity, 2d 654 (74.2) 302 (76.7) 131 (74.5) 106 (69.3)
Multi-morbidity, 3d 283 (32.1) 145 (36.8) 54 (30.7) 34 (22.2)
Mortalitye
Early mortalityf 122 (14.3) 69 (17.7) 23 (13.3) 9 (6.0)
0-30 day mortality 371 (43.4) 209 (53.6) 63 (36.4) 37 (24.8)
ICU: Intensive Care Unit, LOS: Length of stay, BCC: Blood culture collection, IQR: Interquartile range.
a 231 missing information on admission date.
b 207 missing information on BCC location.
c Points: Sepsis (2), TPN (1), Surgery (1), Colonisation (1).
d 2 underlying diseases and 3 underlying diseases.
e Including primary cases-n = 852.
f Mortality before blood cultures became positive for candidaemia.
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100.000 population (Rhodes et al., 2012)) compared with Italy and
France (12.5 and 11.6 beds/100,000 population, respectively),
which requires a more rigorous patient selection process in
Denmark. As such, differences in health care systems and
organisations and patient selection processes complicates com-
parisons of incidence rates according to hospital admissions and
emphasise the need for population-based epidemiological studies.
Compared with previous cohort studies, our patient cohort was
older (median age 66 years versus 53-63 years (Lortholary et al.,
2014; Puig-Asensio et al., 2014; Li et al., 2015; Horn et al., 2009)).
Gastrointestinal disease was the most prevalent underlying
disease and more than twice as common in Denmark as reported
in Australia (52.5% versus 20.8%) (Chen et al., 2006). On the
contrary, solid tumours were less frequent (26.2% vs 30-36%) (Chen
et al., 2006; Luzzati et al., 2016; Puig-Asensio et al., 2014; Almirante
et al., 2005), except in the departments of surgery (39.9%).
Neutropenia was infrequent (3.2%) compared with previous
studies (4.7% to 19%) (Chen et al., 2006; Luzzati et al., 2016;
Puig-Asensio et al., 2014), and the proportion of Danish patients
with haematological disease was low (7.8%) relatively to other
rates (12.5-24.0%) (Lortholary et al., 2014; Chen et al., 2006; Tadec
et al., 2016; Pfaller et al., 2012). Therefore, it seems less likely that
the higher rate of haematological disease in Denmark compared to
the other Nordic countries should explain the higher incidence of
candidaemia as previously suggested (Hesstvedt et al., 2017).To our knowledge, this is the ﬁrst description of multi-
morbidity in candidaemia patients. Unfortunately, this value
cannot be directly compared to previous studies using clinical
scores (e.g. Acute Physiologic And Chronical Health Evaluation
(APACHE) II and Simpliﬁed Acute Physiology Score (SAPS)) (Nucci
et al., 2013; Baldesi et al., 2017; Colombo et al., 2014). However,
multi-morbidity is a simple and pragmatic measurement of the
complexity of underlying diseases and it is applicable in varying
settings (Ording and Sørensen, 2013). Our ﬁnding of 75% of
patients with multi-morbidity illustrates a uniformity of severely
ill patients at the time of candidaemia diagnosis This aligns with
the observed higher overall 30-day mortality (43.4%) compared to
a semi-national survey in Denmark in 2006 and to other
population-based candidaemia studies (37% and 27-31%, respec-
tively) (Chen et al., 2006; Cleveland et al., 2012; Puig-Asensio et al.,
2014; Arendrup et al., 2011b). It also aligns with the notably high
mortality among our candidaemia ICU patients (53.6%) compared
to national 30-day mortality after ICU admission (21.2% overall,
and 36.7% for patients with septic shock) in Denmark in 2011
(Fynbo Christiansen, 2011). A large ICU study from France
compared candidaemia versus non-candidaemia ICU patients
and found a similar difference of 34.6% point in 30-day mortality
(Baldesi et al., 2017). We hypothesise that an increase in multi-
morbidity rates over the past decades, associated with advances in
the management of patients with complicated illnesses, prolonged
intensive caring and blood culturing have contributed to the rise in
Table 3
30-day mortality according to major underlying diseases and risk factors.
Hazard ratioa
(95% CI)
Adjusted
Hazard ratioa
(95% CI)
Minimal adjusted modelb
(Link to causal diagram)
Sex
Female 1 (Ref.) 1 (Ref.) Sex (http://dagitty.net/dags.html?id=12Jr0q)
Male 1.10 (0.89-1.35) -
Age at candidaemia
<75 years 1 (Ref.) 1 (Ref.) Age (http://dagitty.net/dags.html?id=atUl8)
75 years 1.59 (1.29-1.97) -
Prior infection
No 1 (Ref.) 1 (Ref.) Prior infection, age, dialysis, haematology (http://dagitty.net/dags.html?id=uDszw0)
Yes 1.04 (0.84-1.28) 1.05 (0.85-1.30)
Abdominal surgery
No 1 (Ref.) 1 (Ref.) Abdominal surgery, age, gastrointestinal disease: (http://dagitty.net/dags.html?id=T-hiQM)
Yes 0.73 (0.57-0.94) 0.70 (0.54-0.92)
Total parenteral Nutrition
No 1 (Ref.) 1 (Ref.) TPN, age, gastrointestinal disease, multi-morbidity: (http://dagitty.net/dags.html?id=v8-ZGp)
Yes 0.83 (0.65-1.07) 0.91 (0.70-1.18)
Gastrointestinal disease
No 1 (Ref.) 1 (Ref.) Gastrointestinal disease, age: (http://dagitty.net/dags.html?id=mDfau8)
Yes 0.82 (0.67-1.01) 0.85 (0.69-1.04)
Solid cancer
No 1 (Ref.) 1 (Ref.) Solid cancer, age: (http://dagitty.net/dags.html?id=nbSlQ-)
Yes 0.92 (0.71-1.20) 0.81 (0.62-1.06)
Multi-morbidity
1 1 (Ref.) 1 (Ref.) Multi-morbidity, age, haematology: (http://dagitty.net/dags.html?id=eF8Z94)
2 1.05 (0.80-1.36) 1.01 (0.78-1.32)
3 1.23 (0.93-1.61) 1.21 (0.92-1.59)
Candida score
<3 1 (Ref.) 1 (Ref.) Candida score, age, gastrointestinal disease, haematology, multi-morbidity: (http://dagitty.net/dags.html?id=hM9CLO)
3 1.04 (0.78-1.37) 1.06 (0.80-1.41)
CI: Conﬁdence Interval, -: no adjustments performed according to casual diagram.
Ref.: reference.
a Calculated using Cox Regression.
b Minimal adjustment sets for estimating the total effect of each exposure was deﬁned according to casual diagrams and used in the multivariate analyses.
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introduction of new diagnostics and therapeutic options.
This study has limitations. First, a potential heterogeneity in data-
collection as multiple doctors contributed. The use of an abstraction
form sought to minimize this potential bias, which if present may
have led to an underestimation of underlying diseases and risk
factors.Second,patientreferrals between hospitalsanddepartments
and the fact that one third of patients BCs was obtained from an
internal line allowing for possible contamination may have biased
the estimation of incidence. Unfortunately, no other candidaemia
studies have established benchmarks for these issues. However, the
low prevalence of the skin associated C. parapsilosis suggest
contaminations may not be a major bias (van Asbeck et al.,
2009). Third, although intended, attributable mortality was not
assessed due to signiﬁcant challenges in ensuring an objective
evaluation in this heterogeneous and multi-diseased patient
population. Furthermore, it should be kept in mind that these data
unite very different hospital settings and therefore cannot be used
to describe local epidemiology for the different hospitals, but are
useful for comparing with population-based studies.
In conclusion, this study described clinical characteristics of
candidaemia patients based on nationwide data. The high incidence
in Denmark was not explained by high prevalence of haematological
malignancies as previously proposed (Hesstvedt et al., 2017).
However, the underlying disease burden was evident by the high
prevalence of multi-morbidity and high mortality with a substantialproportion of patients dying early. An increasing burden of multi-
morbidity may be expected following better management of
complicated illnesses and as such hypothesise that this may
contribute to the high incidence rate and mortality associated with
candidaemia in our country. This calls for continued surveillance of
candidaemia to target clinical awareness towards these patients.
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